Autologous mesenchymal stem cells for spine fusion: Insights from grape genetic resources

The need to leverage bioactive compounds from natural plant resources to develop and implement targeted therapeutic interventions has gained growing interest among the medical community. This is where this study aims to contribute by introducing an integrative research framework, treating the bone-forming process of MSCs with bioactive compounds from grapes. Following the regression analysis and AHP prioritization as research methodology, data compiled from patient sick lists, stakeholder interview recordings, and medical treatments regarding biocompatibility, bioactive compound efficacy, and osteogenic potential development is comparatively evaluated. The AHP-regression framework can serve as a predictive assessment model and practical decision-making guide for medical stakeholders. There are two main findings of this study. One is that it is the first time to apply a multi-criteria AHP-based chart to show the hierarchical ranking of grape-derived polyphenols in MSC therapy (Alkaline Phosphatase Activity = 0.15 and Calcium Deposition = 0.10). The other is that the framework embraces the relationship between bioactive compounds (coefficient = 1.059 p = 0.044, coefficient = 0.265 p = 0.043) and stem cell differentiation and bone matrix formation. When properly implemented, grape component-based MSC therapy enhanced osteogenic differentiation and mineralization. Finally, this research confirmed that bioactive compounds from grapes can significantly boost the bone-forming process of MSCs.